au.\*:("UK National Cancer Research Institute Lymphoma Clinical Studies Group and the Australasian Leukaemia and Lymphoma Group")
Results 1 to 1 of 1
Selection :
A prospective clinicopathologic study of dose-modified CODOX-M/TVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)MEAD, Graham M; BARRANS, Sharon L; WENDI QIAN et al.Blood. 2008, Vol 112, Num 6, pp 2248-2260, issn 0006-4971, 13 p.Article
